Loading...
Loading...
CGEN| Name | Value |
|---|---|
| Revenues | 6,702.0K |
| Cost of Revenue | 1,552.0K |
| Gross Profit | 5,150.0K |
| Operating Expense | 8,562.0K |
| Operating I/L | -3,412.0K |
| Other Income/Expense | 1,300.0K |
| Interest Income | 1,300.0K |
| Pretax | -2,112.0K |
| Income Tax Expense | 11.0K |
| Net Income/Loss | -2,123.0K |
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on researching, developing, and commercializing therapeutic and product candidates in the field of immuno-oncology. The company's pipeline includes a range of novel antibody-based therapeutics targeting immune checkpoint regulators, with a particular focus on myeloid targets. Compugen has established collaboration agreements with industry leaders such as Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca, as well as research collaborations with institutions like Johns Hopkins University. The company generates revenue through the development and commercialization of its immuno-oncology products and through its collaboration and license agreements with pharmaceutical partners.
